327 related articles for article (PubMed ID: 3049804)
21. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Li JM; Giver CR; Waller EK
Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
[TBL] [Abstract][Full Text] [Related]
22. Role of the thymus in control of autoreactivity or allotolerance in syngeneic and allogeneic bone marrow chimeras treated with bacterial adjuvants.
Taniguchi K; Gondo H; Nomoto K
J Immunol; 1984 Oct; 133(4):1735-9. PubMed ID: 6088626
[TBL] [Abstract][Full Text] [Related]
23. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
Weerasinghe A; Kawamura T; Moroda T; Seki S; Watanabe H; Abo T
Cell Immunol; 1998 Apr; 185(1):14-29. PubMed ID: 9636679
[TBL] [Abstract][Full Text] [Related]
24. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
25. Alloengraftment in IL-2-treated mice.
Sykes M; Pearson DA
Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
[TBL] [Abstract][Full Text] [Related]
26. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
27. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
Jankowski RA; Ildstad ST
Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
[TBL] [Abstract][Full Text] [Related]
28. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
Leshem B; Tsuberi BZ; Lebendiker Z; Anafi-Ayalon M; Shalit M; Weiss L; Slavin S; Kedar E
Transplantation; 1987 Jun; 43(6):814-7. PubMed ID: 2954282
[TBL] [Abstract][Full Text] [Related]
30. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
31. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
32. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
33. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
Soderling CC; Song CW; Blazar BR; Vallera DA
J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of the anti-GVHD effect of IL-2. I. Protective host-type cell populations are not induced by IL-2 treatment alone.
Abraham VS; Sykes M
Bone Marrow Transplant; 1991; 7 Suppl 1():29-32. PubMed ID: 2043882
[TBL] [Abstract][Full Text] [Related]
35. Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat.
Weijtens M; van Spronsen A; Hagenbeek A; de Weger R; Martens A
Exp Hematol; 2004 Oct; 32(10):962-9. PubMed ID: 15504552
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
Sykes M; Eisenthal A; Sachs DH
J Immunol; 1988 May; 140(9):2903-11. PubMed ID: 2966200
[TBL] [Abstract][Full Text] [Related]
37. Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras.
Taniguchi H; Abe M; Shirai T; Fukao K; Nakauchi H
J Immunol; 1995 Dec; 155(12):5631-6. PubMed ID: 7499847
[TBL] [Abstract][Full Text] [Related]
38. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
39. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
[TBL] [Abstract][Full Text] [Related]
40. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]